Thursday, 7 November 2024
  
Login

Australia's most trusted
source of pharma news

Thursday, 07 November 2024
News

Company backs off PBS listing

Posted 6 November 2024 AM

Johnson & Johnson will continue its Australian market stranglehold for Stelara  - for a while longer at least - after the biosimilar most advanced in the PBS listing process threw on the brakes, deciding not to continue with reimbursement at this time.

Amgen has backed away from launching a biosimilar referencing Stelara in Australia. The pharma has two biosimilars of Stelara registered with the TGA, and garnered a PBAC recommendation for Wezlana for "psoriatic arthritis Crohn disease Chronic plaque psoriasis Ulcerative colitis" at the March 2024 meeting.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (15)

Access & Reimbursement (1)

Clinical & Medical, R&D (10)

Regulatory, Pharmacovigilance & QA (3)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.